This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vauthey, J.-N. Articles by Abdalla, E. K. Search for Related Content PubMed PubMed Citation Articles by Vauthey, J.-N. Articles by Abdalla, E. K. Related Articles Related Correspondence Social Bookmarking                            What's this?

Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases

Jean-Nicolas Vauthey, Timothy M. Pawlik, Dario Ribero, Tsung-Teh Wu, Daria Zorzi, Paulo M. Hoff, Henry Q. Xiong, Cathy Eng, Gregory Y. Lauwers, Mari Mino-Kenudson, Mauro Risio, Andrea Muratore, Lorenzo Capussotti, Steven A. Curley, Eddie K. Abdalla

From the Departments of Surgical Oncology, Pathology, and Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Pathology; Massachusetts General Hospital, Boston, MA; and Departments of Pathology and Surgical Oncology, Istituto per la Ricerca e la Cura del Cancro, Torino, Italy.

Address reprint requests to Jean-Nicolas Vauthey, MD, Department of Surgical Oncology, Unit 444, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009; e-mail: jvauthey{at}mdanderson.org

PURPOSE: Chemotherapy before resection of hepatic colorectal metastases (CRM) may cause hepatic injury and affect postoperative outcome.

PATIENTS AND METHODS: Four hundred six patients underwent hepatic resection of CRM between 1992 and 2005. Pathologic review of the nontumorous liver was performed using established criteria for steatosis, steatohepatitis, and sinusoidal injury. The effect of chemotherapy and liver injury on perioperative outcome was analyzed.

RESULTS: One hundred fifty-eight patients (38.9%) received no preoperative chemotherapy, whereas 248 patients (61.1%) did. The median duration of chemotherapy was 16 weeks (range, 2 to 70 weeks). Chemotherapy consisted of fluoropyrimidine-based regimens (fluorouracil [FU] alone, 15.5%; irinotecan plus FU, 23.1%; and oxaliplatin plus FU, 19.5%) and other therapy (3.0%). On pathologic analysis, 36 patients (8.9%) had steatosis, 34 (8.4%) had steatohepatitis, and 22 (5.4%) had sinusoidal dilation. Oxaliplatin was associated with sinusoidal dilation compared with no chemotherapy (18.9% v 1.9%, respectively; P < .001; odds ratio [OR] = 8.3; 95% CI, 2.9 to 23.6). In contrast, irinotecan was associated with steatohepatitis compared with no chemotherapy (20.2% v 4.4%, respectively; P < .001; OR = 5.4; 95% CI, 2.2 to 13.5). Patients with steatohepatitis had an increased 90-day mortality compared with patients who did not have steatohepatitis (14.7% v 1.6%, respectively; P = .001; OR = 10.5; 95% CI, 2.0 to 36.4).

CONCLUSION: Steatohepatitis is associated with an increased 90-day mortality after hepatic surgery. In patients with hepatic CRM, the chemotherapy regimen should be carefully considered because the risk of hepatotoxicity is significant.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients
  Umberto Vespasiani Gentilucci, Daniele Santini, Bruno Vincenzi, Enrica Fiori, Antonio Picardi, and Giuseppe Tonini
  JCO 2006 24: 5467 [Full Text]

This article has been cited by other articles:

				A. Grothey Review: Medical treatment of advanced colorectal cancer in 2009 Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 55 - 68. [Abstract] [PDF]

				J.-N. Vauthey, D. Zorzi, S. Kopetz, E. K. Abdalla, Y. Kishi, and D. G. Blazer III Reply to D.J. Gallagher et al J. Clin. Oncol., July 10, 2009; 27(20): e20 - e21. [Full Text] [PDF]

				B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, M. Ychou, and on behalf of the European Colorectal Metastases Tr Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Ann. Onc., June 1, 2009; 20(6): 985 - 992. [Abstract] [Full Text] [PDF]

				D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., January 1, 2009; 20(1): 5 - 16. [Abstract] [Full Text] [PDF]

				D. G. Blazer III, Y. Kishi, D. M. Maru, S. Kopetz, Y. S. Chun, M. J. Overman, D. Fogelman, C. Eng, D. Z. Chang, H. Wang, et al. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases J. Clin. Oncol., November 20, 2008; 26(33): 5344 - 5351. [Abstract] [Full Text] [PDF]

				S. B. Kesmodel, L. M. Ellis, E. Lin, G. J. Chang, E. K. Abdalla, S. Kopetz, J.-N. Vauthey, M. A. Rodriguez-Bigas, S. A. Curley, and B. W. Feig Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases J. Clin. Oncol., November 10, 2008; 26(32): 5254 - 5260. [Abstract] [Full Text] [PDF]

				L. Capussotti, A. Muratore, F. Baracchi, B. Lelong, A. Ferrero, D. Regge, and J. R. Delpero Portal Vein Ligation as an Efficient Method of Increasing the Future Liver Remnant Volume in the Surgical Treatment of Colorectal Metastases Arch Surg, October 1, 2008; 143(10): 978 - 982. [Abstract] [Full Text] [PDF]

				S. R. Alberts and L. D. Wagman Chemotherapy for Colorectal Cancer Liver Metastases Oncologist, October 1, 2008; 13(10): 1063 - 1073. [Abstract] [Full Text] [PDF]

				J. Ward, J. A. Guthrie, M. B. Sheridan, S. Boyes, J. T. Smith, D. Wilson, J. I. Wyatt, D. Treanor, and P. J. Robinson Sinusoidal Obstructive Syndrome Diagnosed With Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Patients With Chemotherapy-Treated Colorectal Liver Metastases J. Clin. Oncol., September 10, 2008; 26(26): 4304 - 4310. [Abstract] [Full Text] [PDF]

				C. S. Ng, E. K. Abdalla, and J. N. Vauthey Reply Am. J. Roentgenol., February 1, 2008; 190(2): W168 - W168. [Full Text] [PDF]

				B. Atassi, A. K. Bangash, A. Bahrani, G. Pizzi, R. J. Lewandowski, R. K. Ryu, K. T. Sato, V. L. Gates, M. F. Mulcahy, L. Kulik, et al. Multimodality Imaging Following 90Y Radioembolization: A Comprehensive Review and Pictorial Essay RadioGraphics, January 1, 2008; 28(1): 81 - 99. [Abstract] [Full Text] [PDF]

				T. M. Pawlik, R. D. Schulick, and M. A. Choti Expanding Criteria for Resectability of Colorectal Liver Metastases Oncologist, January 1, 2008; 13(1): 51 - 64. [Abstract] [Full Text] [PDF]

				J.-N. Vauthey Colorectal Liver Metastases: Treat Effectively Up Front and Consider the Borderline Resectable J. Clin. Oncol., October 10, 2007; 25(29): 4524 - 4525. [Full Text] [PDF]

				R. Adam, T. Aloia, F. Levi, D. A. Wicherts, R. J. de Haas, B. Paule, M.-P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, et al. Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy J. Clin. Oncol., October 10, 2007; 25(29): 4593 - 4602. [Abstract] [Full Text] [PDF]

				G. K. Dy, J. E. Krook, E. M. Green, D. J. Sargent, T. Delaunoit, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, et al. Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741 J. Clin. Oncol., August 10, 2007; 25(23): 3469 - 3474. [Abstract] [Full Text] [PDF]

				N. Kemeny Presurgical Chemotherapy in Patients Being Considered for Liver Resection Oncologist, July 1, 2007; 12(7): 825 - 839. [Abstract] [Full Text] [PDF]

				Y. Kodama, C. S. Ng, T. T. Wu, G. D. Ayers, S. A. Curley, E. K. Abdalla, J. N. Vauthey, and C. Charnsangavej Comparison of CT Methods for Determining the Fat Content of the Liver Am. J. Roentgenol., May 1, 2007; 188(5): 1307 - 1312. [Abstract] [Full Text] [PDF]

				P.-A. Clavien, H. Petrowsky, M. L. DeOliveira, and R. Graf Strategies for Safer Liver Surgery and Partial Liver Transplantation N. Engl. J. Med., April 12, 2007; 356(15): 1545 - 1559. [Full Text] [PDF]

				R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, A. B. Benson III, C. D. Blanke, R. B. Diasio, A. Grothey, H.-J. Lenz, N. J. Meropol, R. K. Ramanathan, et al. The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer Oncologist, January 1, 2007; 12(1): 38 - 50. [Abstract] [Full Text] [PDF]

				U. V. Gentilucci, D. Santini, B. Vincenzi, E. Fiori, A. Picardi, and G. Tonini Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients J. Clin. Oncol., December 1, 2006; 24(34): 5467 - 5467. [Full Text] [PDF]

				D. Ribero, E. K. Abdalla, and J.-N. Vauthey In Reply J. Clin. Oncol., December 1, 2006; 24(34): 5467 - 5468. [Full Text] [PDF]

				B. Nordlinger and S. Benoist Benefits and Risks of Neoadjuvant Therapy for Liver Metastases J. Clin. Oncol., November 1, 2006; 24(31): 4954 - 4955. [Full Text] [PDF]

				T. Aloia, M. Sebagh, M. Plasse, V. Karam, F. Levi, S. Giacchetti, D. Azoulay, H. Bismuth, D. Castaing, and R. Adam Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver Metastases J. Clin. Oncol., November 1, 2006; 24(31): 4983 - 4990. [Abstract] [Full Text] [PDF]

				Mortality After Surgery for Hepatic Colorectal Metastases Journal Watch Oncology and Hematology, October 16, 2006; 2006(1016): 3 - 3. [Full Text]